Michele Guida

Istituto Tumori Bari — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

38h-index5.7kcitations254works6.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(83), Cancer Immunotherapy and Biomarkers(65), CAR-T cell therapy research(57), Cutaneous Melanoma Detection and Management(51), Immunotherapy and Immune Responses(41)

Publications253 total

High BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitors
Journal of Translational Medicine·2025Open Access
528 A novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution identified predictive spatial biomarkers in immunotherapy- and targeted therapy-treated melanoma patients
Regular and Young Investigator Award Abstracts·2025Open Access
1212 Immunomodulation beyond the tumor microenvironment: FRC reprogramming in melanoma-draining lymph nodes
Regular and Young Investigator Award Abstracts·2025Open Access
1605MO Primary results from a randomized phase II trial of BNT111 in combination with cemiplimab with calibrator monotherapy arms in anti-PD-(L)1 relapsed/refractory melanoma
Annals of Oncology·2025· 1 cited
Baseline metabolic signatures predict clinical outcomes in immunotherapy-treated melanoma patients: a pilot study
Frontiers in Immunology·2025Open Access
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)
Journal for ImmunoTherapy of Cancer·2025· 4 citedOpen Access
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Journal of Clinical Oncology·2025· 1 cited
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study
European Journal of Cancer·2025· 1 citedOpen Access
Tebentafusp in metastatic uveal melanoma patients: Results of the Italian expanded access program.
Journal of Clinical Oncology·2025· 1 cited
Application of a novel multiplex imaging-based immunotherapy panel and AI-powered analysis solution for predictive spatial biomarker identification on immunotherapy-treated melanoma patients.
Journal of Clinical Oncology·2025
Long-term outcomes after discontinuation of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC) in the POD1UM-201 trial.
Journal of Clinical Oncology·2025
Serum thymidine kinase activity (TKa) as a potential biomarker in the sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma (SECOMBIT) trial.
Journal of Clinical Oncology·2025· 1 cited
Final results of POD1UM-201, a phase 2 study of retifanlimab, a humanized anti–PD-1 antibody, in patients with advanced or metastatic Merkel cell carcinoma (MCC).
Journal of Clinical Oncology·2025· 2 cited
Spatial proteomics of the tumor microenvironment in melanoma: current insights and future directions
Frontiers in Immunology·2025· 6 citedOpen Access
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Journal of Clinical Oncology·2025· 4 cited
Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
Journal of Experimental & Clinical Cancer Research·2025· 3 citedOpen Access
The Role Of Gynecologic Expert Ultrasound In The Evaluation Of Pelvic Masses: A Rare Case Of Pelvic Recurrence Of Solitary Fibrous Tumor
International Journal of Gynecological Cancer·2025· 1 cited
Italian interim analysis of the multinational, post-authorisation safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma: focus on time to onset of adverse events
EJC Skin Cancer·2025Open Access
Corrigendum: The molecular tumor board as a step in cancer patient management: a southern Italian experience
Frontiers in Medicine·2024Open Access
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma
NEJM Evidence·2024· 7 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Paolo A. Ascierto(21), Vanna Chiarion‐Sileni(18), Paola Queirolo(18), Mario Mandalà(14), Michele Maio(12), Sabino Strippoli(12), Paolo Marchetti(10), Michele Del Vecchio(10), Pietro Quaglino(10), Piotr Rutkowski(9), Anna Maria Di Giacomo(8), Francesco Spagnolo(8), Jacopo Pigozzo(8), Massimo Guidoboni(7), Ruggero Ridolfi(7), Laura Ridolfi(6), Pier Francesco Ferrucci(6), Ester Simeone(6), Alessandro Testori(6), Virginia Ferraresi(5)